Boston Scientific Corporation (BSX), one of the world's largest medical device makers, has endured a punishing stretch. After trading near $109 within the past year, shares now change hands around $48, leaving investors to ask a single pressing question: can the stock claw its way back to the $60 mark?
$60 has become a focal point for Boston Scientific's stock price target discussion because it sits squarely in the middle of Wall Street's current forecast range. After a wave of analyst price-target cuts in 2026, the median target now lands right at $60, with several major firms—including Mizuho, BTIG, and Jefferies—settling on that figure. For investors, $60 represents both a realistic recovery milestone and a round psychological level that, if reclaimed, would signal the market is regaining confidence in the company's growth story.
Boston Scientific designs and markets minimally invasive devices across cardiology, endoscopy, urology, and neuromodulation. The company has long been a medtech growth leader, but that narrative cracked in 2026. The core problem is the Watchman left atrial appendage closure franchise, a key driver of structural-heart sales, together with the electrophysiology (EP) business—segments that combined represent roughly a quarter of total revenue.
U.S. standalone Watchman procedure volumes fell by low-double-digit percentages as physicians adopted an "ablate and wait" approach following clinical trial readouts, while EP growth slowed amid intensifying pulsed-field ablation competition. Management twice lowered full-year organic revenue growth guidance, from a 7%–8.5% range down to 5%–6%. The shares responded by sliding more than 50% from their highs.
Importantly, the underlying business is not shrinking. Second-quarter 2026 revenue rose about 7.5% year over year to $5.44 billion, with adjusted earnings per share of $0.86 beating consensus. The decline reflects a repricing of growth expectations rather than collapsing demand.
Several factors support a recovery. First, valuation now appears historically undemanding, with the stock trading near a forward price-to-earnings ratio around 14–15x—among the lowest in the S&P 500 for a large-cap medtech name. Second, the company announced a global restructuring program targeting roughly $500 million in annual pre-tax savings, with much of it earmarked for reinvestment in growth initiatives.
Third, Boston Scientific retains a broad, diversified portfolio and a deep pipeline across heart-rhythm, structural-heart, and peripheral-intervention markets. If Watchman volumes stabilize and new product launches—such as next-generation ablation and lithotripsy systems—gain traction, the market could reward the company with multiple expansion back toward historical levels.
The path to $60 is not without friction. Watchman headwinds are expected to persist into early next year, and EP growth guidance has been cut to flat-to-low-single-digit in the U.S. even as the broader market grows faster, signaling share pressure. Fourteen analysts have revised earnings estimates lower in recent months, and further guidance reductions could extend the de-rating.
Macro and sector risks also loom, including hospital capital-spending constraints, potential tariff and currency effects, and the integration costs associated with recent acquisitions. Any renewed slowdown in procedure volumes would undermine the recovery thesis.
Despite the turbulence, the sell-side consensus remains optimistic. Across more than 30 analysts, the average 12-month price target sits near $62–$63, with the median at $60 and individual estimates ranging from roughly $44 to $94. The consensus rating is a "Buy." This dispersion reflects genuine uncertainty: the low end implies little upside, while the high end assumes a full recovery of confidence. A move to $60 would require not only operational stabilization but also a willingness among investors to pay a richer multiple once again.
From a technical analysis perspective, the $42.20 level—the stock's 52-week low—serves as the critical support zone that has so far held. Nearby, the $45–$47 area has provided a base in recent months. On the upside, $50 represents the first meaningful psychological resistance, followed by the $60 target itself, which coincides with the median analyst objective. A sustained close above $50 would be an early signal that buyers are regaining control, while $60 remains the larger supply zone that must be cleared to confirm a durable trend change.
For traders seeking to navigate shifts like those seen in Boston Scientific, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to stay ahead of changing conditions. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market behavior, technical patterns, and AI-driven analysis. Traders can use these signals to uncover new opportunities, monitor existing positions, and identify shifting market trends more efficiently than manual review alone. For those watching whether BSX can reclaim $60, automated signal monitoring can provide an additional layer of timing insight.
A return to $60 for Boston Scientific is realistic over a 12-month horizon, but far from assured. The strongest arguments in its favor are a depressed valuation, a still-positive revenue trajectory, a substantial cost-cutting program, and a sell-side consensus that has largely maintained Buy ratings even while trimming targets. The primary risks are continued weakness in Watchman and EP, additional guidance cuts, and persistent multiple compression. Investors should monitor procedure-volume commentary, the pace of new product launches, and whether the stock can hold above $42 and reclaim the $50 level—the first stepping stone on any sustained journey back toward $60.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BSX has been closely correlated with ISRG. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if BSX jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To BSX | 1D Price Change % | ||
|---|---|---|---|---|
| BSX | 100% | -0.28% | ||
| ISRG - BSX | 71% Closely correlated | +2.41% | ||
| MMSI - BSX | 56% Loosely correlated | -0.13% | ||
| ALC - BSX | 49% Loosely correlated | -0.78% | ||
| MDT - BSX | 46% Loosely correlated | -0.72% | ||
| NTRA - BSX | 45% Loosely correlated | +0.86% | ||
More | ||||
| Ticker / NAME | Correlation To BSX | 1D Price Change % |
|---|---|---|
| BSX | 100% | -0.28% |
| BSX (2 stocks) | 14% Poorly correlated | +1.07% |
| Medical/Nursing Services (141 stocks) | 1% Poorly correlated | +0.38% |
| Health Services (242 stocks) | 1% Poorly correlated | +0.38% |